Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a
"sugar pill") to determine if its use will prevent weight gain after liver transplantation
(LT). In addition, researchers will be testing to determine if semaglutide prevents the
development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic
Resonance Imaging (MRI) and laboratory results.